Share on StockTwits

Ocular Therapeutix’s (NASDAQ:OCUL) quiet period is set to end on Wednesday, September 3rd. Ocular Therapeutix had issued 5,000,000 shares in its IPO on July 25th, American Banking and Market News reports. The total size of the offering was $65,000,000 based on an initial share price of $13.00. During the company’s quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Several analysts have recently commented on the stock. Analysts at Cowen and Company initiated coverage on shares of Ocular Therapeutix in a research note on Tuesday, August 19th. They set an “outperform” rating and a $40.00 price target on the stock. Separately, analysts at Oppenheimer initiated coverage on shares of Ocular Therapeutix in a research note on Tuesday, August 19th. They set an “outperform” rating and a $25.00 price target on the stock. Finally, analysts at RBC Capital initiated coverage on shares of Ocular Therapeutix in a research note on Tuesday, August 19th. They set an “outperform” rating and a $21.00 price target on the stock.

Shares of Ocular Therapeutix (NASDAQ:OCUL) traded up 2.55% on Tuesday, hitting $16.8899. The stock had a trading volume of 2,250 shares. Ocular Therapeutix has a 52 week low of $11.90 and a 52 week high of $16.97. The stock has a 50-day moving average of $14.18 and a 200-day moving average of $14.18. The company’s market cap is $51.6 million.

Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology.

Receive News & Ratings for Ocular Therapeutix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.